Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 20Terminated 3Unknown 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Sarcoma 6Myeloid 6Lymphoid 5Plasma cell 3Dermatologic 2Classical hematology 2CNS 2Breast 2Tumor-Agnostic 1Other neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

PRETEXT I Hepatoblastoma 1

Interventions

Oxaliplatin 95Fluorouracil 84Capecitabine 75Gemcitabine 72Leucovorin 68Nivolumab 67Bevacizumab 63pembrolizumab 60Magnetic Resonance Spectroscopy 52Specimen Handling 50Irinotecan 50durvalumab 46Radiotherapy 42atezolizumab 40Cisplatin 39Paclitaxel 37Biopsy 37130-nm albumin-bound paclitaxel 34Cetuximab 30Carboplatin 27Albumin-Bound Paclitaxel 26Taxes 24Drug Therapy 20dehydroftorafur 19Radiation 19Ipilimumab 19tislelizumab 18Surgical Procedures, Operative 17Standard of Care 17Docetaxel 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sirolimus × Gastrointestinal × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡